Early-phase study data from the University of Colorado Cancer Center member Sapna Patel, MD, suggest that anzutresgene autoleucel (anzu-cel), a PRAME-directed T-cell therapy, is effective and tolerable in patients with advanced uveal melanoma, a rare and hard-to-treat eye cancer. The therapy achieved a 67% objective response rate and 88% disease control rate, with manageable side effects.